Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland.
Nat Med. 2012 May 4;18(5):736-49. doi: 10.1038/nm.2754.
Current therapies for asthma and allergy are relatively safe and effective at controlling symptoms but do not change the chronic course of disease. There is no established method to prevent asthma and allergy, and major unmet needs in this area include the better control of the severe forms of these diseases and the developments of curative therapies. Two major therapeutic strategies for asthma and allergy are currently being developed, and I here discuss the advances and challenges for future therapeutic development in these two areas. The first approach, allergen-specific immunotherapy, aims to induce specific immune tolerance and has a long-term disease-modifying effect. The second approach is the use of biological immune response modifiers to decrease pathological immune responses. Combination strategies using both of these approaches may also provide a route for addressing the unmet clinical needs in allergic diseases.
目前用于哮喘和过敏的治疗方法在控制症状方面相对安全有效，但不能改变疾病的慢性进程。目前尚无预防哮喘和过敏的既定方法，该领域的主要未满足需求包括更好地控制这些疾病的严重形式，以及开发治愈疗法。目前正在开发两种哮喘和过敏的主要治疗策略，我在这里讨论这两个领域未来治疗开发的进展和挑战。第一种方法是变应原特异性免疫疗法，旨在诱导特异性免疫耐受，并具有长期的疾病修饰作用。第二种方法是使用生物免疫反应调节剂来减少病理性免疫反应。这两种方法的联合策略也可能为解决过敏疾病的未满足临床需求提供途径。
